How does Tesamorelin + Ipamorelin Blend's half-life affect dosing?

Tesamorelin + Ipamorelin Blend has a plasma half-life of Mixed, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1x daily subq dosing at 1 mg tesamorelin + 200 mcg ipamorelin per dose explains the typical onset timeline for scheduling and cycle endpoints.

What does Tesamorelin + Ipamorelin Blend stack well with?

For protocol / scheduling / cycling protocols, Tesamorelin + Ipamorelin Blend pairs with compounds on complementary pathways: BPC-157, TB-500, Ipamorelin. These pairings are selected because they engage independent receptor systems from Tesamorelin + Ipamorelin Blend's primary mechanism (Tesamorelin engages the GHRH receptor; ipamorelin engages the GHSR), producing additive or synergistic effects rather than receptor competition.

Should I cycle Tesamorelin + Ipamorelin Blend?

Standard cycle for Tesamorelin + Ipamorelin Blend is 8–12 weeks of 1x daily subq 1 mg tesamorelin + 200 mcg ipamorelin dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to Tesamorelin + Ipamorelin Blend's Mixed half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

What is the regulatory status of Tesamorelin + Ipamorelin Blend?

Tesamorelin + Ipamorelin Blend regulatory status: Tesamorelin alone approved; blend unapproved in the United States; WADA status both banned (s2); research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Is Tesamorelin + Ipamorelin Blend safe during pregnancy or breastfeeding?

Tesamorelin + Ipamorelin Blend, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Home/ Compounds/ Tesamorelin + Ipamorelin Blend

Tesamorelin + Ipamorelin Blend

Protocol

For protocol designers building Tesamorelin + Ipamorelin Blend into a multi-compound regimen, the practical questions are pharmacokinetic compatibility, route compatibility, receptor non-overlap, and operational scheduling around real-world constraints (travel, meals, training). The 1 mg tesamorelin + 200 mcg ipamorelin 1x daily subq dose at Mixed half-life informs which scheduling pattern fits.

Protocol / Scheduling / Cycling Applications

Periodised CyclesDaily TimingTapered CyclesTravel ConsiderationsStack Scheduling

Key Takeaways

Scheduling lens: Tesamorelin + Ipamorelin Blend's Mixed half-life via subq places it in the daily-dosing bucket.
Mechanism: Tesamorelin engages the GHRH receptor; ipamorelin engages the GHSR.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Tesamorelin engages the GHRH receptor; ipamorelin engages the GHSR. Pathways converge on the somatotroph for multiplicative GH release. Ipamorelin's selectivity avoids cortisol and prolactin elevation. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Tesamorelin + Ipamorelin Blend.

Cycle length and off-cycle planning

Standard Tesamorelin + Ipamorelin Blend cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Daily and weekly timing

Tesamorelin + Ipamorelin Blend with a Mixed half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1x daily SubQ, with consistency mattering more than the absolute clock time of any single dose.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Tesamorelin + Ipamorelin Blend protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Tesamorelin + Ipamorelin Blend schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Protocol / Scheduling / Cycling Applications

Stack Scheduling

For stack scheduling scheduling, Tesamorelin + Ipamorelin Blend is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Multi-Peptide Timing

The most-asked scheduling question for Tesamorelin + Ipamorelin Blend in multi-peptide timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Periodised Cycles

Schedule design for Tesamorelin + Ipamorelin Blend in periodised cycles starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Off-Time

For off-time scheduling, Tesamorelin + Ipamorelin Blend is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1 mg tesamorelin + 200 mcg ipamorelin	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1 mg tesamorelin + 200 mcg ipamorelin	4–6 weeks initial cycle
Protocol focus	SubQ	1 mg tesamorelin + 200 mcg ipamorelin	1x daily SubQ
Maintenance phase	SubQ	1 mg tesamorelin + 200 mcg ipamorelin	Ongoing with periodic pauses

Dose timing for Tesamorelin + Ipamorelin Blend is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

Tesamorelin + Ipamorelin Blend stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Tesamorelin + Ipamorelin Blend + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Tesamorelin + Ipamorelin Blend's mechanism in protocol / scheduling / cycling protocols.
Tesamorelin + Ipamorelin Blend + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Tesamorelin + Ipamorelin Blend's mechanism in protocol / scheduling / cycling protocols.
Tesamorelin + Ipamorelin Blend + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Tesamorelin + Ipamorelin Blend's mechanism in protocol / scheduling / cycling protocols.
Tesamorelin + Ipamorelin Blend + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Tesamorelin + Ipamorelin Blend's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Both banned (S2) FDA: Tesamorelin alone approved; blend unapproved

Combined profiles. Monitor IGF-1.

Lens-specific safety considerations for protocol / scheduling / cycling use of Tesamorelin + Ipamorelin Blend: Combined profiles. Monitor IGF-1. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Ipamorelin selectivity

PMID 9849822

Tesamorelin + Ipamorelin Blend vs Related Peptides

Compound	Profile	Onset	Best For
Tesamorelin + Ipamorelin Blend	GHRH + GHRP combination	Mixed	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Cycle length and off-cycle period?

Standard cycle for Tesamorelin + Ipamorelin Blend is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

What is the evidence base for Tesamorelin + Ipamorelin Blend?

Tesamorelin + Ipamorelin Blend's evidence base sits at research level investigational. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The protocol / scheduling / cycling interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What is the standard dosing protocol for Tesamorelin + Ipamorelin Blend?

Conventional Tesamorelin + Ipamorelin Blend dosing is 1 mg tesamorelin + 200 mcg ipamorelin 1x daily subq via subq. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Clinical Protocol

Start a Tesamorelin + Ipamorelin Blend Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Tesamorelin + Ipamorelin Blend and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: Variable
Half-life: Mixed
WADA: Both banned (S2)
FDA: Tesamorelin alone approved; blend unapproved

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Tesamorelin + Ipamorelin Blend unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Tesamorelin + Ipamorelin Blend

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised